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ABSTRACT 
We used live imaging by fiber-optic confocal microendoscopy (CME) of yellow 
fluorescent-protein (YFP) expression in motor neurons to observe and monitor 
axonal and neuromuscular synaptic phenotypes in mutant mice. First, we visualized 
slow degeneration of axons and motor nerve terminals at neuromuscular junctions 
following sciatic nerve injury in WldS mice with slow Wallerian degeneration. 
Protection of axotomised motor nerve terminals was much weaker in WldS 
heterozygotes than in homozygotes. We then induced covert modifiers of axonal and 
synaptic degeneration in heterozygous WldS mice, by N-ethyl-N-nitrosourea (ENU)-
mutagenesis, and used CME to identify candidate mutants that either enhanced or 
suppressed axonal or synaptic degeneration. From 219 of the F1 progeny of ENU-
mutagenized BALB/c mice and thy1.2-YFP16/WldS mice, CME revealed six 
phenodeviants with suppression of synaptic degeneration. Inheritance of synaptic 
protection was confirmed in three of these founders, with evidence of Mendelian 
inheritance of a dominant mutation in one of them (designated CEMOP_S5). We 
next applied CME repeatedly to living WldS mice and to SOD1G93A mice, an animal 
model of motor neuron disease, and observed degeneration of identified 
neuromuscular synapses over a 1-4 day period in both of these mutant lines. Finally, 
we used CME to observe slow axonal regeneration in the ENU-mutant ostes mouse 
strain. The data show that CME can be used to monitor covert axonal and 
neuromuscular synaptic pathology and, when combined with mutagenesis, to identify 
genetic modifiers of its progression in vivo. 
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INTRODUCTION 
 
Many neurodegenerative diseases, ranging from Amyotrophic Lateral Sclerosis 
(ALS) to Alzheimer’s Disease, remain intractable despite more than a decade of 
research using mutants and transgenic models in mice and other species (Bruijn and 
Cleveland, 1996; Bruijn et al., 2004; Gotz et al., 2007; Gotz and Ittner, 2008; Jackson 
et al., 2002). However, discovery of novel pathways for neuroprotection or 
enhancement of regeneration in animal models continues to be important for 
identifying new targets for treatment of disease.  One approach is through genome-
wide mutagenesis, a powerful methodology that has generated new animal models 
and provided insight into cell biological mechanisms of development and normal 
physiological functions.  
 
Screening for mutations generated by N-ethyl-N-nitrosourea (ENU) in mice is one 
proven method for discovery of novel gene functions. For instance, mutant 
phenotypes identified by ENU-mutagenesis screens have led to better understanding 
of diseases ranging from complex behavioral dysfunctions to autoimmune disorders 
(for recent reviews see (Acevedo-Arozena et al., 2008; Cook et al., 2006; Godinho 
and Nolan, 2006; Gondo, 2008).  ENU screens are required to achieve sufficient 
throughput to identify mutants within a relatively short overall time frame. They 
should also be non-invasive, or minimally-invasive, since phenodeviant founders 
identified in a screen are the only resource for breeding and testing of inheritance of 
the deviant phenotype(s). Standardized protocols such as SHIRPA (Nolan et al., 
2000) readily expose overt neurological phenotypes in ENU screens. However, these 
methods are less suitable for identifying covert phenotypes that may be protective, or 
otherwise beneficial, and thus producing no overt neurological signs. Such 
phenotypes will normally be missed in primary screens that are restricted to detection 
of external or behavioural anomalies.  
 
The most compelling precedent for discovery and importance of covert, 
neuroprotective phenotypes was the serendipitous finding of slow Wallerian 
degeneration in the spontaneous mutant WldS mouse. In these mice, orthograde 
degeneration of distal axons after nerve injury is delayed by 1-4 weeks (Lunn et al., 
1989; Lyon et al., 1993; Perry et al., 1990b).  Once this remarkable phenotype had 
been established, systematic molecular genetic analysis was then used to show that 
the mutation underlying it encodes a chimeric Ube4b-Nmnat1 protein that, when 
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expressed in transgenic mice, reproduces the slow-degeneration of axons and 
neuromuscular synapses observed in the natural mutant (Coleman et al., 1998; 
Conforti et al., 2000; Mack et al., 2001). Subsequent detailed phenotypic analysis 
showed that axon protection in peripheral nerves of WldS mice following nerve 
section is very strong: distal axons are preserved for 21 days or more after the nerve 
injury (Lunn et al., 1990; Perry et al., 1990a; Perry et al., 1992; Perry et al., 1990b). 
The amount of axon protection also varies in a ‘gene-dose’ dependent fashion: that 
is, the number of preserved axons in a low stringency assay performed at 3 days 
after nerve section showed variation among transgenic mouse lines as a function of 
their WldS protein expression (Mack et al., 2001).  
 
Interestingly, Western-blot analysis of brain and quantitative measurements of 
immunostaining for WldS protein in brain and spinal cord show expression levels in 
heterozygotes at about half the level in homozygotes. However, the level of axon 
protection in WldS heterozygotes is virtually the same as in homozygotes (Beirowski 
et al., 2005; Mack et al., 2001; Wilbrey et al., 2008).  Despite this, protection of axons 
by the WldS gene in both the native mutant and in the transgenic equivalents is 
stronger than that of motor nerve terminals, suggesting that degeneration of motor 
nerve terminals may be regulated differently from axons (Gillingwater and 
Ribchester, 2001; Gillingwater et al., 2002). Synaptic protection further declines with 
age: thus, in WldS mice aged over about 8 months very few intact motor nerve 
terminals are present by 3 days after nerve injury (Gillingwater et al., 2002; Perry et 
al., 1992; Ribchester et al., 1995). Subsequent cross-breeding of WldS mice with 
mouse models of neuropathy and neurodegenerative disease, showed that WldS 
mitigates onset and progression of disease signs in some but not others, including 
mouse models of familial ALS (Ferri et al., 2003; Fischer et al., 2005; Kariya et al., 
2008; Rose et al., 2008; Samsam et al., 2003; Vande Velde et al., 2004). This 
neuroprotective weakness may result from the age-dependent or gene dose-
dependent decline in the capacity of WldS protein to adequately protect synapses 
(Gillingwater et al., 2002). 
 
Thus, the fortuitous discovery of the WldS phenotype is highly instructive in several 
respects. First, it proves that beneficial, neuroprotective mutations may be 
undetectable using conventional screening methods based on clinical observation of 
behaviour. Second, it establishes a compelling and urgent case for systematic 
screening, in order to identify additional mutants with covert, neuroprotective 
phenotypes. Third, the benefits of one type of neuroprotective mutation may not be 
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transferable to all forms of neurodegenerative disease, so one goal of systematic 
screening is to find mutations that are more effective in mitigating disease onset or 
progression than WldS. Finally, new methods are clearly required to carry out such 
systematic screening effectively if potentially-beneficial phenotypes are to be 
recognized unequivocally, in the absence of overt clinical signs.  
 
Our principal aim in the present study was to find genetic modifiers that would 
enhance synaptic protection in WldS mice. In order to identify these modifiers 
(phenodeviants), we first developed a method for screening axonal and 
neuromuscular synaptic phenotypes in living mice based on fiber-optic confocal 
microendoscopy (CME; (Pelled et al., 2006; Vincent et al., 2006). We then induced 
genomic mutations using ethylnitrosourea (ENU) and screened for mutations that 
affected (enhanced or suppressed) axonal or synaptic degeneration in WldS mice 
using CME. Specifically, we crossbred ENU-mutagenized BALB/C mice with thy1.2-
YFP16/WldS transgenic mice that express Yellow Fluorescent Protein (YFP) in motor 
neurons (Bridge et al., 2007; Feng et al., 2000) and employed CME to assess the 
preservation of morphology of axons and neuromuscular junctions following nerve 
section in the adult F1 offspring. Once the breeding pipeline for mutagenised mice 
had been established, the screen had a relatively high throughput (that is, it enabled 
WldS-modifiers to be identified on a shorter time scale than more conventional ENU-
screening methods in mice). We identified several phenodeviants that were 
subsequently tested for inheritance, including re-assessment of axonal and 
neuromuscular synaptic protection using CME. We also extended the CME 
methodology to investigation of covert synaptic pathology in the well-established 
transgenic SOD1G93A mouse model of ALS, which shows early onset of disease signs 
in motor axons and NMJ’s (David et al., 2007; Frey et al., 2000; Gurney et al., 1994; 
Pun et al., 2006; Schaefer et al., 2005; Turner and Talbot, 2008). Finally we applied 
CME to the ostes mutant mouse, which was identified from a previous ENU-
mutagenesis screen using standard SHIRPA screening protocols(Mackenzie et al., 
2009), and which shows defects in axon regeneration (Mackenzie et al., 2007). 
Together, the results prove that CME and genomic mutagenesis can be combined in 
a powerful, flexible and versatile approach to investigation of neuromuscular biology 
and pathology at a cellular level in vivo. 
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RESULTS 
Neuromuscular synapses degenerate more rapidly in WldS heterozygotes than 
homozygotes. 
We showed previously that in young adult (1-2 month old) homozygous WldS mice 
most neuromuscular synapses degenerate within 4-10 days of axotomy (Bridge et 
al., 2007; Gillingwater et al., 2002; Mack et al., 2001). Electrophysiological recording 
and analysis of neuromuscular synaptic transmission in double homozygous thy1.2-
YFP16:WldS mice also showed no difference in the rate of synaptic degeneration 
following axotomy in these mice compared with those that did not express the YFP 
reporter (Bridge et al., 2007). Conventional confocal microscopy of muscles in 
thy1.2-YFP16:WldS mice supported these previous findings but additionally revealed 
striking differences in neuromuscular synaptic protection in WldS homozygotes 
compared with heterozygotes (Figure 1A-F). In this cohort, the rate of synaptic 
degeneration in WldS heterozgotes was virtually indistinguishable from that in wild-
type mice: 24-48 hours after sciatic nerve section, motor endplates were vacant, 
uncovered by motor nerve terminals in both genotypes (Figure 1G). By 3 days there 
was therefore a clear distinction between almost complete preservation of motor 
nerve terminals in WldS homozyogtes, in contrast to almost complete synaptic 
degeneration in WldS heterozygotes. This distinction was evident despite 
indistinguishable levels of protection in the axotomized tibial nerve axons in 
homozygotes and heterozygotes at this time point (see below).  
 
In light of the striking difference in synaptic protection in WldS heterozygotes and 
homozygotes, we envisaged using young adult heterozygous WldS mice as a 
sensitized background for seeking modifiers of axonal and synaptic degeneration. 
We reasoned also that a basal protective level of WldS protein, mitigating Wallerian 
degeneration of axons, would facilitate detection of protective mutations that might 
selectively suppress degeneration of synapses. In other words, normal Wallerian 
degeneration might obscure weak synaptic-protection phenotypes but WldS would 
delay this. Likewise, using WldS as a sensitised background also provided a more 
prolonged time-window for detecting mutations that might accelerate Wallerian 
degeneration of axons.  
 
CME distinguishes intact from degenerating axons and synapses. 
We developed a method for screening ENU-mutants, based on direct in vivo imaging 
of axons and neuromuscular junctions using fibre-optic confocal microendoscopy 
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(CME). To validate this method, we first used CME to visualise intact axons and 
NMJ’s in the tibial nerve on one side in WldS and wild-type mice, employing a 
standard, hand-held 1.5 mm diameter Proflex S-1500 optical-fiber probe. By 
manipulating the endoscopic probe tip through the same skin-aperture used to 
visualize the tibial nerve, we were able to visualize neuromuscular junctions (NMJ’s) 
in the muscles adjacent to the tibial nerve, including the medial gastrocnemius 
muscle (Figure 2 A,B; Supplementary Movie 1). In order to minimise trauma, we took 
care not to force the probe tip through either the perineurial of epimysial sheaths. 
The probe tip was only applied to, manoeuvred and glided over the surfaces of the 
exposed tibial nerve and gastrocnemius muscle, through small (less than 5mm) 
incisions in the skin.  
 
Next, we established that CME would allow us to recognise and distinguish protected 
from degenerating motor nerve terminals after unilateral section of the sciatic nerve 
under anaesthesia. We reanaesthetised mice 3 days after sciatic nerve section and 
used CME to image the distal axons in the tibial nerve and gastrocnemius NMJ’s, as 
in unoperated mice. As expected (Gillingwater et al., 2002; Winlow and Usherwood, 
1975), CME in thy1.2-YFP16 mice – wild type for WldS - revealed that all the tibial 
nerve axons were fragmented and there were no intact axons or nerve terminals 
visible in 3-days denervated gastrocnemius muscle (n=11; Figure 2C).  Also 
expected, the appearance of YFP-fluorescent axons in the 3-days axotomized distal 
tibial nerve of young adult homozygous WldS mice was similar to those of unoperated 
control mice and distinct from the fragmented appearance of degenerating axons in 
wild-type mice (compare Figures 2C and 2D). Intact motor nerve terminals were also 
readily observed in the axotomized gastrocnemius muscles of thy1.2-YFP16/WldS 
homozygous mice (Figure 2E; Supplementary Movie 2). However, axons and NMJ’s 
in heterozygous WldS mice showed intact axons in the tibial nerve only (Figure 2D) 
with complete degeneration of intramuscular axons and motor nerve terminals in the 
gastrocnemius muscle (Figure 2F).  
 
In further preparation for a mutagenesis screen, we established the likelihood of 
false-positives in heterozygous WldS mice: that is, spontaneous deviation from the 
characteristic phenotype (that is, synaptic protection being present 3 days after 
axotomy when it was expected to be absent in WldS/+ heterozygotes). In a sample of 
20 F1-generation mice, produced by crossing BALB/c male mice with thy1.2-
YFP16/WldS double-homozygous females, CME images showed intact axons and 
degenerated gastrocenmius NMJ’s three days after axotomy in all of them. These 
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data therefore suggest that the probability of observing synaptic protection by chance 
in a WldS heterozygote, 3 days after axotomy, is less than 5%. (Further data 
presented below suggest it is less than 2%). The data also indicated there is no 
constitutive enhancement or suppression of the WldS/+ phenotype in C57BL/6-
BALB/c hybrid mice. 
 
In sum, CME readily distinguishes intact axons and NMJ’s from those undergoing 
Wallerian degeneration. We therefore concluded that in vivo imaging by CME at a 
single time point, 3 days after axotomy, would readily allow us to recognize the 
effects of additional genomic mutations, either in enhancing and accelerating axon 
degeneration, or in suppressing and retarding synaptic degeneration at NMJ’s in 
WldS mice.  
 
ENU induces modifiers of axonal and synaptic degeneration in WldS mice 
Figure 3 shows the design of the modifier screen, which combined ENU mutagenesis 
in BALB/c mice, cross breeding with thy1.2-YFP16/WldS double-homozygotes; and 
then cutting the sciatic nerve in the 1-2 month old F1 offspring (heterozygous for 
WldS) and assessing the outcome 3 days later using CME. As described above, the 
tibial nerve and gastrocnemius muscle were exposed through a small skin incision 
and the tibial nerve axons and locations of NMJ’s in gastrocnemius or other nearby 
muscles were examined using CME.  We screened 219 F1 progeny of ENU-
mutagenized mice on the sensitized WldS/+ background in accordance with this 
protocol. One of these mice evidently bore an ENU-induced mutation that 
constitutively produced an abnormally kinked tail. This incidence (approximately 
1/200) of an overt phenotype endorses the efficacy of ENU as a mutagen in this 
cohort and is consistent with assessment using the SHIRPA methodology in previous 
ENU-screens (Nolan et al., 2000). None of the other mice showed any clinically overt 
phenotype with respect to their appearance or behaviour. 
 
Seven mice in the ENU-mutagenized F1 cohort showed covert variations in synaptic 
or axonal phenotype compared with non-mutagenized WldS/+ mice. We classified 
these phenodeviants as CEMOP_S and CEMOP_A according to the respective 
cellular localization of the phenotype (CEMOP: Confocal microEndoscopic 
MOtoneuron Phenotype; _Axons or _Synapses). Mice CEMOP_S1 to S6 showed 
enhanced synaptic protection, varying from intact terminal axon branches and motor 
nerve terminals, to partial fragmentation of these presynaptic structures. Images of 
gastrocnemius NMJ’s obtained from three of these mice are shown in Figure 4A-C 
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and real-time imaging sequences from CEMOP_S2 and S5, which showed the 
strongest synaptic protection, are shown in Supplementary Movies 3 and 4. 
Subjectively, mice CEMOP_S3, S4 and S6 showed weaker synaptic protection than 
the others in this primary screen but nevertheless there was better protection in 
these phenodeviants than we have observed in any unmutagenized WldS/+ 
heterozygote (data not shown). Conversely, mouse CEMOP_A1 showed complete 
degeneration of neuromuscular synapses but also increased fragmentation of the 
axons (Figure 4D), indicating reduced protection of axons normally observed in 
WldS/+ heterozygotes: that is, enhancement of Wallerian degeneration. All the other 
F1 mice screened using CME displayed the characteristic neuromuscular phenotype 
expected of WldS/+ mice: that is, with intact tibial nerve axons but complete 
degeneration of motor innervation of gastrocnemius muscles. Almost all these 
phenotypcially-unremarkable mice were sacrificed before recovery from anaesthesia. 
 
All seven phenodeviant, CEMOP_S1-6 and CEMOP_A1, mice were recovered from 
anaesthesia and crossed with either wild-type mice or WldS homozygotes to test for 
inheritance of their phenotypes. Mice from these F2 litters were anaesthetized at age 
1-2 months and the sciatic nerve was sectioned unilaterally. They were 
reanaesthetized 3 days later and CME was used to visualize the tibial nerves and 
innervation of the gastrocnemius muscle, in the same fashion that was used to 
discover the founders.  
 
The inheritance data are summarised in Table 1. Thus far, we have obtained 
compelling evidence for inheritance in two lines, CEMOP_S3 and CEMOP_S5 
(Supplementary Figure S1; Supplementary Movie 5). None of the F2 mice that were 
negative for WldS in the litters showed evidence of synaptic protection. However, 4 
out of 7 mice in the first litter from CEMOPS_5 that were genotyped as WldS 
heterozygotes (2 males and 2 females) showed evidence of synaptic protection 3 
days after section of the sciatic nerve. Two additional litters derived from the 
CEMOPS_5 founder yielded a further 6 out 10 WldS/+ offspring that also showed 
neuromuscular synaptic protection at 3 days post axotomy. One of these mice was 
sacrificed and protection of neuromuscular synapses was confirmed in isolated 
lumbrical muscles using conventional confocal microscopy (Supplementary Figure 
S1). These ratios therefore constitute convincing evidence that line CEMOP_S5 
carries an autosomal-dominant, ENU-induced mutation that delays synaptic 
degeneration, most likely by affecting the same pathways influenced by the 
neuroprotective mechanism of the WldS gene.  
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Line CEMOP_S3 also showed evidence of inheritance but as yet we have insufficient 
data due to poor breeding and offspring-yield of the founder to conclude that this is 
Mendelian. Line CEMOP_S2 showed evidence of inheritance but, despite evidence 
of very strong synaptic protection in the founder (Figure 3B; Supplementary Movie 3), 
the numbers of offspring with a synaptic-protection phenotype (2/15 WldS/+ mice) 
suggesting only poor inheritance of the ENU-mutation, for which we are unable to 
provide a compelling explanation at present. In the remaining four CEMOP_S lines 
there was no evidence of inheritance of the deviant phenotype (Table 1). These four 
inheritance-negative mice are useful, however, because they allow us to place a 
revised, conservative upper bound of 4/219 (less than 2%) on the incidence of 
spontaneous phenodeviation with synaptic protection (ie phenotypic outliers) in 
WldS/+ heterozygous mice at 3 days post axotomy. By contrast, based on the 
number of offspring showing the same phenodeviation from the WldS/+ phenotype in 
the CEMOP_S5 line, the probability that the incidence of synaptic protection in the 
offspring derived from the founder was due to chance, rather than inheritance, is 
extremely low (less than 1.6 x 10-7). This evidence therefore strongly suggests that 
CEMOP_S5 is a novel, Mendelian-dominant neuroprotective mutant that probably 
modifies the effect of WldS on its signalling pathways.  
 
CME visualizes degenerating neuromuscular junctions in longitudinal studies 
of  living mice 
The discriminatory power of the CME technique led us naturally to inquire whether 
CME could be extended to longitudinal studies to monitor the degeneration of 
identified motor units, by repeated imaging of neuromuscular junctions in individual 
mice. We proved this principle both in WldS mice and in the SOD1G93A transgenic 
mouse model of motor neuron disease.  
 
Figure 5 shows a group of NMJ’s identified in the flexor digitorum longus muscle, 
adjacent to the tibial nerve, in a homozygous thy1.2-YFP16:WldS mouse that was 
reanaesthetised and imaged at daily intervals, 3-5 days after sciatic nerve section. 
These images suggest that once synaptic degeneration is initiated in WldS motor 
units, the retraction of motor nerve terminals and degeneration of the axon collaterals 
that supply them can occur within less than 24 hrs. 
 
Next, we applied CME to a preliminary study of neuromuscular synaptic 
degeneration in transgenic mice that incorporate a low number (7-15) of copies of the 
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mutant human SOD1 gene, SOD1G93A. These mice have a later onset and slower 
progression of disease than the more commonly-studied high (>20) copy-number  
strain (Alexander et al., 2004; Veldink et al., 2003). Low copy-number SOD1G93A mice 
begin to show abnormal motor reflexes and gait, or weakness in one or both 
hindlimbs, from about 4-10 months of age. We crossbred SOD1G93A transgenic mice 
with thy1.2-YFP16 mice to generate the required fluorescent reporter in the diseased 
motor neurons.  
 
CME was used to image NMJ’s in two 3-month old (asymptomatic) and two 8-month 
old (symptomatic), double hemizygous thy1.2-YFP16/SOD1G93A mice. The older mice 
showed liminal abnormalities of gait and hindlimb weakness (one of these in shown 
in Supplementary Movie 6). The mice were anaesthetized and images of tibial nerve 
axons and gastrocnemius NMJ’s were recorded. Four days later, the mice were re-
anaesthetized and the tibial nerve axons and gastrocnemius NMJ’s were re-
examined. Intact axons and NMJ’s were readily detected using CME in control, age-
matched SOD1G93A-negative mice that were littermates of the thy1.2-
YFP16/SOD1G93A mice (Supplementary Figure S2). Validation was carried out by 
conventional confocal microscopy of isolated and fixed tibial nerves and hind limb 
muscles after sacrificing the animals at the end of the second viewing.  
 
In the mouse shown in Supplementary Movie 6, a group of intramuscular collateral 
axon branches identified on initial viewing was re-identified during the second 
session. Some motor nerve terminals that were intact on the first viewing had 
evidently degenerated by the second (Figure 6 A,B; Supplementary Movies 7,8). 
Other NMJ’s were supplied by thin or beaded preterminal axons. Sometimes 
collateral branches were completely disconnected from their original endplates 
(Figure 4C) referred to by others as a ‘winter tree’ appearance (Schaefer et al., 
2005). Other junctions showed evidence of compensatory nerve terminal sprouting 
(Supplementary Figure S2). Thinning of preterminal axons and denervation of motor 
endplates was also observed in other muscles in these mice, verified post mortem 
using conventional confocal microscopy (Figure 4D). Although we also succeeded in 
relocating groups of NMJ’s in the two 13-week old asymptomatic SOD1G93A we have 
not as yet found convincing evidence from CME that synapses undergo degeneration 
in advance of overt clinical signs of disease (data not shown).  
 
These observations underscore the capability of CME to detect and monitor 
pathological signs of spontaneous synaptic degneration in mice. It is most unlikely 
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that degeneration of motor nerve terminals was caused by the CME imaging 
technique itself, for three main reasons. First, the neuromuscular abnormalities we 
observed were also present at neuromuscular junctions in end-stage SOD1G93A mice 
that had not been subjected to CME (Figure 6E); second there was minimal 
possibility of mechanical damage by manipulation of the microendoscope itself 
because the short working distance of the probe required it to be glided over the 
surfaces of the exposed nerve and muscle, and we never penetrated the perineurial 
or epimysial sheaths with the probe tip. Third, in accordance with the above, most 
neuromuscular junctions examined in the SOD1G93A mice, including those reimaged 
in asymptomatic mice, were unaltered by the repeated viewing and there was also no 
sign of axon degeneration following repeated imaging of the tibial nerve 
(Supplementary Figure S2). 
 
CME captures slow axonal regeneration in ostes mice. 
Finally, we asked whether CME was sensitive enough to monitor differences in 
peripheral nerve regeneration (Pelled et al., 2006; Vincent et al., 2006). For these 
experiments we imaged regenerating axons in the neuromuscular ENU-mutant 
ostes, identified in a separate dominant ENU screen using SHIRPA analysis (Nolan 
et al., 2000). These mice have an overt neurological phenotype (tremor and muscle 
weakness) and a complex underlying neuromuscular phenotype(Mackenzie et al., 
2009). Independent experiments also demonstrated slow axon regeneration after 
peripheral nerve injury in homozygous ostes mice (Mackenzie et al., 2007). We 
compared axonal regeneration in thy1.2-YFP16:ostes in homozygotes, 
heterozygotes and their age-matched wild-type littermates. The mice were re-
anaesthetized 10-30 days after unilateral sciatic nerve crush and the axons and 
neuromuscular junctions of the distal tibial nerve and gastrocnemius muscles were 
exposed through small skin apertures as described above.   
 
CME confirmed the delayed axonal regeneration in homozygous and heterozygous 
ostes mice (Figure 7A-C). By 10 days, few regenerating axons had reached the tibial 
nerve in ostes/+ heterozygotes compared with wild-type littermates and none had 
regenerated in homozygotes. This was verified post mortem, by conventional 
confocal microscopy of the tibial nerve (Figure 7D-F). By 20 days, CME of the tibial 
nerve indicated similar levels of regeneration in all three groups of mice 
(Supplementary Figure S3) but conventional microscopy of lumbrical muscles 
showed most endplates reinnervated only in wild-type and ostes/+ heterozygotes 
(Figure 7G-I).   By 30 days, virtually all motor endplates in the lumbrical muscles of 
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the ostes/+ heterozygotes were reinnervated but ostes/ostes homozygotes still 
showed fewer reinnervated endplates (data not shown).  
 
DISCUSSION  
We have shown here how ENU-mutagenesis when combined with CME establishes 
an effective platform for identifying covert deviations in the pattern or rate of axonal 
and neuromuscular synaptic degeneration and regeneration. The phenodeviants and 
mutants we identified in the WldS-modifier screen would have been undetectable 
using conventional screening methods. The potential diagnostic value of CME is also 
underscored by the proof that that this technique enables minimally-invasive, 
longitudinal imaging of axons or motor nerve terminals undergoing degeneration and 
regeneration following nerve injury, or in an animal model of ALS. Several studies 
suggest that widespread malfunction or degeneration of motor axons and their 
terminals occur in neurodegenerative diseases before overt impairment of motor 
function is detected (David et al., 2007; Fischer et al., 2004; Frey et al., 2000; Gurney 
et al., 1994; Pun et al., 2006; Ravits et al., 2007; Schaefer et al., 2005). Further 
developments of CME technology and identification of the mechanisms of synaptic 
protection in the mutants we identify using it may therefore provided a basis for 
robust or routine examination then monitoring of treatment from early stages in 
progression of neuromuscular disease. 
 
Our screening method has potential for high throughput: with the present design and, 
once a pipeline of breeding and surgical preparation is established, a trained single 
investigator can readily screen between 10-20 mutagenised mouse lines per day, a 
rate we achieved towards the end of the present study (see Methods). The number 
of phenodeviants we detected (7 out of 219 ENU/WldS mice screened) is consistent 
with the incidence of phenodeviation in other modifier screens (Carpinelli et al., 2004; 
Rubio-Aliaga et al., 2007). Not all these phenodeviants showed germ-line 
transmission of their phenotypes, however. Failure of inheritance tests following 
detection of phenodeviants in founder animals sometimes is a general feature of 
modifier-screens perhaps owing to polygenic inheritance, a background-sensitive low 
penetrance mutation, or the result of a stochastic event (P.Nolan, personal 
communication). However, our compelling evidence for inheritance of mutations that 
protects synapses, especially in the CEMOP_S5 line, both vindicates and validates 
CME as a basis for rapid screening for covert phenotypes.  
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How useful might the modifiers of synaptic degeneration we identified become? 
Transfer of WldS expression itself has proved to be ineffective on disease onset or 
progression by ectopic expression in transgenic mouse models of ALS (Fischer et 
al., 2005; Vande Velde et al., 2004) or spinal muscular atrophy (Kariya et al., 2008; 
Rose et al., 2008), although caution should be exercised in interpreting any lack of 
protective effects on NMJ’s when only a single allele of WldS is present (ie in 
heterozygotes); or where disease signs are of late onset, owing to the weak 
protection of axons and NMJ’s conferred by WldS in aged mice (Fischer et al., 2005; 
Gillingwater et al., 2002; Perry et al., 1992; Ribchester et al., 1995). However, co-
expression of WldS has been shown to partially block degeneration in axonal 
disorders including dysmyelination (Samsam et al., 2003), motor neuropathy (Ferri et 
al., 2003), axonal spheroid pathology (Mi et al., 2005)  and taxol toxicity (Wang et al., 
2002). It remains to be shown whether the protective benefits of CEMOP_S5 can be 
transferred to mouse models of ALS or other neurodegenerative diseases. Continued 
screening for similar covert mutant phenotypes is also warranted, to maximize 
chances of detecting additional mutations, only some of whose effects might be 
sufficient to arrest disease progression in animal models of disease (see, for 
example, Kieran et al., 2005). Thus, we may anticipate that one or more mutations 
identified by combining mutagenesis with CME will lead to significant improvements 
in protection of neuromuscular synapses, increasing the resources that might 
ultimately be used to understand or treat neuromuscular disease.  
 
Why seek modifiers in a model of delayed Wallerian degeneration (WldS mice) rather 
than, for example, in the well-established SOD1G93A animal model of ALS? The main 
reason is that the WldS mutation is well suited as a sensitized background for 
detection of modifiers of axonal or synaptic degeneration, because the onset of 
degeneration is triggered simultaneously in all axons by a surgical nerve lesion. 
Degeneration then progresses over a well-defined, relatively brief time course with 
little heterogeneity between axons (Beirowski et al., 2005; Beirowski et al., 2004; 
Bridge et al., 2007; Gillingwater et al., 2002). A modified form of our experimental 
design could have been used, in principle, to find beneficial modifiers of early 
neuromuscular synaptic and axonal degeneration in SOD1G93A mutant mice (David et 
al., 2007; Fischer et al., 2004; Pun et al., 2006; Schaefer et al., 2005) and perhaps 
now this should be attempted. However, the unpredictable variation in the onset and 
endpoints of disease in SOD1G93A mice places significant additional constraints on 
the design of screens that might be capable of detecting deviations from stages in 
the disease progression (Benatar, 2007; Schnabel, 2008; Scott et al., 2008). 
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Refinement of the CME method and its application to longitudinal study and 
monitoring of disease signs in mouse models of ALS offers an attractive prospect for 
overcoming the limitations in interpretation of most studies on SOD1G93A transgenic 
mice due to variability in the onset of disease signs in this line.  
 
The physiological mechanisms of action of mutations such CEMOP_S5 - or others 
arising from the mutatgenesis screen – could, like WldS, involve modification of 
transcription or translation of other genes (Gillingwater et al., 2006; Wishart et al., 
2007b); or by direct modification of intracellular signalling (see (Beirowski et al., 
2009; Conforti et al., 2007; Wilbrey et al., 2008); or by targeting enzymic activity to 
intracellular compartments that are pivotal in regulating energy metabolism (Conforti 
et al., 2009). Establishing the gene mutations will be the most important step towards 
identifying their mechanism of action. The discovery and analysis of the spontaneous 
WldS mutant, though more complex than a point mutation, is instructive. The 
phenotype was discovered serendipitously. The gene was then identified, by 
positional cloning then reconstitution of phenotype in transgenic mice (Coleman et 
al., 1998; Lunn et al., 1989; Lyon et al., 1993; Mack et al., 2001). A similar strategy 
has been successfully used to establish the locus of point mutations that produce 
neurodegeneration (Kieran et al., 2005); Mackenzie et al., 2009). Recent 
methodologies for high-throughput, fast genomic sequencing may facilitate the 
identification the locus and nature of the mutation in the CEMOPS_5 and 
CEMOPS_3 mutants identified by the present screening method (Olson, 2007).  
 
We have also shown that CME is a viable technique for monitoring differences in 
axon regeneration in mutants in vivo. It is possible to monitor axon degeneration and 
regeneration non-invasively in small mammals at low resolution using techniques 
ranging from transcutaneous imaging with a fluorescence dissecting microscope 
(Pan et al., 2003) to magnetic resonance imaging (Bendszus and Stoll, 2005). 
Although CME is more invasive, it provides the optical resolution required to visualize 
single axons, and to distinguish fragmented, degenerating axons from thin, 
regenerating axons (Schaefer et al., 2005), as well as capacity to detect 
abnormalities in the form of regenerating neuromuscular synapses. Neither of these 
can be resolved with present non-invasive, low-resolution methods. The ostes/+ mice 
we studied here demonstrate the facility for CME to detect mutants that show 
deviations from normal patterns or the rate of axon regeneration and these mice 
themselves represent a potentially powerful resource as a sensitized genetic 
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background for a further ENU mutagenesis screen, designed to expose novel covert 
motor neuron regeneration phenotypes.  
 
How suitable might CME be for visualizing subtle defects in neuromuscular pathology 
in vivo? Visualization of neuromuscular junctions in vivo using conventional 
fluorescence microscopy has been established over many years as a technique for 
repeated imaging and has yielded considerable biological insights into the plasticity 
of NMJ’s in development, aging and disease (Balice-Gordon and Lichtman, 1990; 
Misgeld and Kerschensteiner, 2006; Schaefer et al., 2005; Walsh and Lichtman, 
2003). Recently, mulitphoton-microscopy using gradient refractive-index (GRIN) 
lenses, has successfully been applied to visualisation of muscle structure and 
function in mice and humans (Barretto et al., 2009; Llewellyn et al., 2008). While the 
CME method has a theoretical spatial resolution of only 2-5 µm, which is much lower 
than either conventional water immersion objectives or GRIN lenses, it has the 
advantages of being faster, less invasive and more versatile than either conventional 
confocal or multiphoton microscopy. For instance, imaging NMJ using conventional 
optics requires stabilization and artificial ventilation of a deeply anaesthetized animal, 
with exposure of a relatively large area of muscle to admit the tip of a long-working 
distance water-dipping objective. Mice enduring this invasive and relatively lengthy 
procedure are likely to be at higher risk of subsequent health problems; and animal 
welfare is of paramount concern for the viability of the line, not least the capacity to 
test for inheritance of a deviant phenotype and to generate sufficient mice for 
mapping and identifying the mutation. Multiphoton imaging via GRIN lenses has 
been shown to be feasible in mice and in humans but with limited flexibility and 
requiring sensitive, specialized (and relatively expensive) equipment. By contrast, 
CME is flexible, minimally-invasive and therefore suitable for high-throughput, 
genome-wide mutagenesis screening and for longitudinal investigation of 
neuromuscular abnormalities. The probe diameter is smaller than most biopsy 
needles (Tobina et al., 2009). Thus, a variant of the CME method may prove suitable 
for longitudinal examination of NMJ’s in humans.  
 
In summary, we have shown that mutants with covert enhancement or suppression 
of synaptic degeneration can be produced by ENU-mutagenesis, supporting the 
hypothesis that degeneration of synaptic terminals is regulated differently and 
perhaps independently from that of axons or neuronal cell bodies (Gillingwater & 
Ribchester, 2001, 2003). CME is a practical method for visualising synaptic 
degeneration in vivo; and longitudinal study of covert neuromuscular phenotypes can 
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be efficiently performed using this flexible and minimally-invasive imaging technique. 
In the long run, the biological resources generated in the present study and future 
applications of CME may lead to more effective monitoring and treatment of 
neuromuscular disease. 
 
 
 
EXPERIMENTAL METHODS 
 
Mouse strains 
The strains used included: BALB/c mice (Charles River); WldS mutant mice on a 
C57BL/6 background (Harlan UK); transgenic mouse line thy1.2-YFP16 (Feng et al., 
2000); a low (7-15) copy-number strain of SOD1G93A transgenic mice, specifically 
B6.Cg-Tg(SOD1-G93A)1Gur/J (Jackson Laboratory, Bar Harbor, Maine), carrying 
the G93A mutant form of the human SOD1 transgene; and ostes mice identified in a 
separate ENU-mutagenesis screen and established on a mixed BALB/c:FVB 
background (Mackenzie et al., 2009) . Mutagenized mice were produced following a 
protocol of ENU injection in BALB/C male mice as previously described (Justice et 
al., 2000). WldS mice were bred to homozygosity into thy1.2-YFP16 mice by 
recurrent backcrosses to generate double homozygotes for WldS and thy1.2-YFP16.  
YFP16:SOD1G93A lines were established by breeding fertile SOD1G93A males with 
homozygous thy1.2-YFP16 females. Similarly, ostes mice were also crossed with the 
transgenic line thy1.2-YFP16 to generate homozygous and heterozygous ostes mice 
with fluorescent motor neurons. Animal studies were conducted under the guidance 
issued by the UK Medical Research Council (Medical Research Council 
Responsibility In the Use of Animals for Medical Research (Medical Research 
Council, London, 1993)) and UK Home Office Welfare guidelines (Home Office 
Project Licence no. 30/2287).  Mice had free access to water (25 ppm chlorine) and 
were fed ad libitum on a commercial diet (SDS maintenance diet) containing 2.6% 
saturated fat.   
 
DNA Extraction and Genotyping 
Mice were genotyped for WldS using quantitative real-time PCR (Wishart et al., 
2007a).  For genotyping SOD1G93A mice, genomic DNA was extracted from earclips 
using alkaline lysis in 50mM  NaOH. Mice were genotyped for human SOD1G93A, 
using primers 5'-CAT CAG  CCC TAA TCC ATC TGA-3' and 5'-CGC GAC TAA CAA 
TCA AAG TGA-3' (236bp  product)(Rosen et al., 1993) and mouse alpha- Synuclein 
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5'-AGA AGA CCA AAG AGC AAG TGA CA-3' and 5'-ATC TGG TCC TTC TTG ACA 
AAG C-3' (130bp product) as an internal control. PCR amplification was performed 
using Platinum PFX (Invitrogen, Paisley, UK) in 2x amplification buffer and the PCR 
products, 130bp and 236bp respectively, were separated by agarose gel 
electrophoresis. For WldS and ostes mouse genotyping, genomic DNA was extracted 
from mouse tail tips using Nucleon BACC2 DNA purification kit (Tepnel Life Sciences 
PLC) according to manufacturer’s instructions with the following modifications: 1) tail 
tips of 2.5mm were directly placed in 200µl of Reagent B, Proteinase K was added at 
200 µg/ml and the mixture incubated overnight at 55°C.  2) DNA was resuspended in 
50 µl of double-distilled water and stored at -20°C as a stock solution. Ostes mice 
were genotyped by PCR amplification and analysed by single-stranded 
conformational polymorphism (SSCP) using the following primers: TGGTA GAAGA 
GAACC CACTT CC (forward) and TCTTT ACTCA TGGTT GGTGC AT (reverse).  
Mice carrying the thy1.2-YFP16 transgene were identified by the presence of 
fluorescent axons in fresh ear-punches, using a standard fluorescence compound 
microscope.   
 
Surgery 
Mice were prepared for surgery with a subcutaneous injection of 100 µl of 
Vetergesic® (buprenorphine 4.2µg/ml) following anaesthesia by inhalation of 3-5% 
isoflurane/O2 (1 litre/min). The sciatic nerve was exposed unilaterally through a small 
incision at mid-thigh level and the nerve either sectioned with scissors or crushed 
firmly between the jaws of watchmakers forceps for 30s. The continuity of the 
perineurial sheath of the sciatic nerve after nerve crush was checked in situ. Skin 
wounds were closed with silk suture.  
 
Analysis of axonal and synaptic morphology 
For in vivo analysis, severed sciatic nerve axons located distally in the tibial nerve 
and superficial neuromuscular junctions in the gastrocnemius muscle were visualized 
via a small (<5 mm) incision in the skin. A Proflex S-1500 fiber-optic probe with a tip 
diameter of 1500 µm was connected to either Mauna Kea Technologies CellVizio or 
Leica FCM1000 confocal microendoscopes. The laser scanning units had an 
excitation wavelength of 488 nm with a collection bandwidth of 505 nm – 700 nm.  
Images were captured at 12 frames/second The probe tip was normally manipulated 
by hand through the skin wound while monitoring the images acquired in real time 
using ImageCell software running on Apple Mac computers supplied with the 
Molecular and Cellular Neuroscience, Volume 42, Issue 4, November 2009, Pages 296–307 
http://dx.doi.org/10.1016/j.mcn.2009.08.002
 19 
instrument. Once we had established the routine procedure for the screen, the mean 
time of the final imaging session, from induction of anaesthesia through CME 
imaging, appraisal of axonal and neuromuscular phenotype, to wound-suture and 
recovery or sacrifice of the mouse, was 12.5+1.8 minutes (mean+S.D.) per mouse. 
Conventional confocal microscopy was performed on whole mounts fixed in 4 % 
paraformaldehyde for 30-60 minutes, counterstained with TRITC-α-bungarotoxin to 
label acetylcholine receptors, washed in phosphate-buffered saline and mounted in 
Vectashield or Mowiol, using either a Leica SP5 or BioRad Radiance 2000 confocal 
microscopes. Scoring of endplate occupancy was normally done at low power  (4x-
20x objectives) while viewing with conventional fluorescence optics, or from 
montages of whole muscles made by digital stitching of contiguous z-series obtained 
using the confocal microscope. An endplate was scored as vacant if there was no 
discernible evidence of any contact by an overlying YFP-positive motor nerve 
terminal with the TRITC-α-bungarotoxin stained motor endplate area. 
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 Table/ Figure Legends 
Table 1 
Inheritance test results of phenodeviants identified in the ENU-mutagensis/ 
CME screen.   
One phenodeviant with enhanced axon degeneration and six phenodeviants with 
suppression of synaptic degeneration were identified in the screen. Inheritance test 
results from wild-type (+/+) mice were negative (0%) for all phenodeviants showing 
synaptic protection and WldS/+ inheritance test results of CEMOP_A1, CEMOP_S1, 
CEMOP_S4 and CEMOP_S6 were also negative (0%).  WldS/+ inheritance test 
results of CEMOP_S2 was 12.5%, possibly due to a low penetrance mutation. 
WldS/+ inheritance test results of CEMOP_S3 and CEMOP_S5 were approximately 
31% and 68% respectively suggesting Mendelian inheritance of a dominant mutation 
at least in the case of CEMOP_S5.   
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Figure 1 
Motor nerve terminals are not protected from Wallerian degeneration in WldS 
heterozygotes 
Conventional confocal microscopic images of distal tibial nerve axons (A-C) and 
neuromuscular junctions in deep lumbrical muscles (DL; D-F) three days after 
ipsilateral section of the sciatic nerve. Axons and nerve terminals are labelled via 
transgenic expression of YFP. Postsynaptic acetylcholine receptors were labelled 
with TRITC–α–Bungarotoxin to visualise motor endplates. Axons and motor nerve 
terminals degenerate rapidly in wild-type (+/+; A,D). Axons are protected in WldS 
heterozygotes (B,E), which express about half the level of mutant protein compared 
with homozygotes, but motor nerve terminals are not. Both axons and nerve 
terminals are protected in WldS homozygotes (C,F). The time course of synaptic 
degeneration (G) was measured by scoring the percentage of all endplates in whole-
mounts of DL muscles (about 250 fibers per muscle) that were ‘vacant’: that is, with 
no overlying YFP positive terminal (as in D,E). The rate of degeneration of nerve 
terminals in wild-type mice is not discernibly different from that in WldS heterozygotes 
and both are much more rapid than degeneration of motor nerve terminals in WldS 
homozygotes. Each point represents mean data from up to four lumbrical muscles 
from three to four mice (total number of axotomized lumbrical muscles examined D-
33; E-56; F-29).  Smooth curves shown are empirical fits to the data, for clarity only. 
Calibration bar: 50 µm. 
 
Figure 2 
CME resolved intact from degenerating axons or neuromuscular synapses 
A. Low power view through a dissecting microscope of the Proflex 1.5 mm probe 
used to image the tibial nerve, exposed through a small skin incision, and the 
adjacent gastrocnemius muscle. B: intramuscular axons and motor nerve terminals in 
an innervated thy1.2-YFP16 mouse gastrocnemius muscle with an intact sciatic 
nerve. C: Axons in the tibial nerve of thy1.2-YFP16 mice all degenerated by 3 days 
after section of the sciatic nerve, in contrast to the extensive axonal protection seen 
in WldS mouse nerves. D: Axotomized tibial nerve axons are also preserved 3 days 
after sciatic nerve section in thy1.2YFP16-WldS heterozygotes, indistinguishable from 
wild-type and axotomised WldS homozygotes (data not shown). E. Intact NMJ’s in the 
gastrocnemius muscle of a WldS homozygote were observable with CME 3 days after 
sciatic nerve injury but, F: no intact NMJ’s were ever seen in thy1.2-YFP/WldS 
heterozygotes at this time point. 
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Figure 3   
Schematic representation of the CME driven ENU screen. thy1.2-YFP16/WldS 
double homozygous female mice on a C57BL/6 background were crossed to ENU-
mutagenized BALB/c male mice. The sciatic nerves of the ENU-WldS/+ F1 offspring 
were transacted unilaterally under anaesthesia at 4-6 weeks of age. Following 
recovery 3 days later, the mice were reanaesthetized. The distal axons of the 
severed sciatic nerve were visualized in the tibial nerve via a small (< 5mm) incision 
in the skin, using a 1.5mm diameter fiber-optic probe connected to the CME 
computer. Superficial neuromuscular junctions were then visualized in the 
gastrocnemius muscle by manipulating the probe tip within the same cutaneous 
aperture. Mice showing deviation from the normal phenotype of WldS/+ mice: 
specifically those showing greater axonal degeneration (CEMOP_A) or stronger 
synaptic protection (CEMOP_S) than expected, were recovered from anaesthesia 
and subsequently transferred to breeding schedules to test for inheritance of the 
deviant phenotype.  
 
Figure 4 
Imaging with CME distinguishes intact from degenerating NMJ’s and axons in 
WldS mice and ENU-phenodeviants. A-C Evidence of synaptic protection in three 
F1 ENU/ thy1.2-YFP/WldS crosses, 3 days after sciatic nerve section (CEMOP_S1, 
S2 and S5). All these phenodeviants were genetically heterozygous for WldS. These 
images were all obtained from sequences (movies) captured at 12 frames per 
second. Movies from phenodeviants CEMOP_S3 and CEMOP_S5 are shown in 
Supplementary Movies 3 & 4. D: Fragmented axons were observed 3 days after 
sciatic nerve section in the tibial nerve of ENU-mutant CEMOP_A1 that was 
heterozygous for WldS. 
 
Figure 5 
CME enables In vivo time-lapse imaging of synaptic degeneration at 
axotomised neuromuscular junctions in WldS mice 
CME images of a group of neuromuscular junctions in a homozygous thy1.2-
YFP16/WldS flexor digitorum longus muscle A) 3 days; B) 4 days; C) 5 days after 
section of the sciatic nerve. Arrows indicate neuromuscular junctions that 
degenerated over the two successive 24 hour periods. 
 
 
Molecular and Cellular Neuroscience, Volume 42, Issue 4, November 2009, Pages 296–307 
http://dx.doi.org/10.1016/j.mcn.2009.08.002
 30 
Figure 6 
Imaging NMJ’s with CME shows synapse loss in thy1.2-YFP16/SOD1G93A mice. 
A, B : images of a group of gastrocnemius NMJ’s obtained four days apart. Motor 
nerve terminals indicated by arrows in A had evidently degenerated by the time of 
the second viewing in B. These images were obtained from real-time movies 
obtained using CME (Supplementary Movies 2 & 3). Neuromuscular abnormalities 
including thinning of preterminal axons and degeneration of motor nerve terminals 
were also detected using this method (C, arrows). These features of neuromuscular 
pathology were also observed using conventional confocal microscopy, D: in a 
lumbrical muscles from the same mouse post-mortem; and E: in another SOD1 
mouse sacrificied at end-stage of disease. 
 
Figure 7 
Slow axonal regeneration is also detected in ENU-mutant ostes using CME. A-
C: The CME technique also proved effective in monitoring slow axonal regeneration 
in thy1.2YFP-ostes ENU mutant mice. A: wild-type mouse tibial nerve, 10 days after 
crush injury of the sciatic nerve. Extensive axon regeneration is evident by presence 
of intact axons. B: discernibly fewer axons regenerated in ostes heterozygotes at the 
same time point indicating a slower rate of regeneration. C: In ostes homozygotes 
continuous axons were not observed in the tibial nerve 10 days after sciatic crush, 
only autofluorescence in the vicinity of the degenerated axons could be seen, 
indicating even slower regeneration. D-F: corresponding images from the tibial 
nerves of the same mice obtained by conventional confocal microscopic post 
mortem: G-H: Conventional confocal microscopy of neuromuscular junctions in 
lumbrical muscles of wild-type (G), ostes/+ (H) and ostes/ostes (I) mice 20 days after 
sciatic nerve crush.  NMJ’s were fully reinnervated in wild-type (G) mice, whereas 
there is only partially reinnervation in ostes/+ (H) mice shown by the presence of 
some vacant endplates.  NMJ’s in ostes/ostes mice were completely vacant and 
therefore not reinnervated (I). 
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Supplementary Figures: 
 
Supplementary Figure S1 
Synaptic protection in CEMOP_S5 is inherited. The CEMOP_S5 founder, 
heterozygous for thy1.2-YFP:16 and WldS, was crossed to a C57BL6 control mouse 
that was homozygous for thy1.2-YFP:16.  The twelve mice obtained in the first litter 
shown were genotyped for the WldS allele by real-time PCR. Still images captured 
from sequences using CME are shown for the mice with its litter identification code 
on the top left of each image. The image sequence from mouse 1.1j is shown in 
Supplementary Movie 5. All the wild-type mice show fragmented nerve endings, but 
four out of seven heterozygous WldS mice show protected intramuscular collaterals 
and motor nerve terminals (arrows).  Mouse 1.1a was sacrificed and the lumbrical 
muscles were dissected and the conventional confocal image (colour image, upper 
right) confirmed the strong synaptic protection observed using CME.   
 
Supplementary Figure S2 
Visualization of NMJ’s axons and in SOD1G93A mice using CME 
A: Intact NMJ’s visualized by CME in a control, SOD1G93A-negative littermate of the 
mouse shown in Supplementary Movie 6 (and NMJ’s in Figure 6A-C).  
B: Evidence of axonal sprouting (arrow) visualized by CME in a SOD1G93A 
symptomatic mouse. C: Intact tibial nerve axons visualized by CME in the SOD1G93A 
mouse shown in Supplementary Movie 6 (gastrocnemius NMJ’s shown in Figure 6A). 
D: Intact tibial nerve axons visualized by CME in the SOD1G93A mouse shown in 
Supplementary Movie 6 (gastrocnemius NMJ’s shown in Figure 6B), obtained four 
days after the image shown in C. There is no evidence of axonal degeneration 
suggesting the initial visualization did not cause photodamage to the YFP-fluorescent 
axons. 
 
Supplementary Figure S3 
Axonal regeneration and reinnervation of NMJs in Ostes mice.   
Axons were fully regenerated in wild-type (A) and ostes/+ (B) mice 20 days after 
sciatic nerve crush, however axons in ostes/ostes (C) were less dense, indicating a 
slower rate of regeneration.  At 30 day post-crush, axons have fully regenerated in 
wild-type (D), ostes/+ (E) and ostes/ostes (F) mice.  There was no discernible 
difference between the axons of these mice (D-F). 
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Supplementary Movies 
Supplementary Movie 1: Real-time images obtained by CME showing intact 
intramuscular axons and neuromuscular junctions in a control, unoperated thy1.2-
YFP16 mouse. One of the frames from this movie is shown in Figure 3A. 
 
Supplementary Movie 2: Real-time images obtained by CME showing intact 
intramuscular axons and neuromuscular junctions in the gastrocnemius muscle of a 
thy1.2-YFP16/WldS homozygote, 3 days after section of the sciatic nerve. One of the 
frames from this movie is shown in Figure 3B. 
 
Supplementary Movie 3: Real-time images obtained by CME showing intact 
intramuscular axons and neuromuscular junctions in the gastrocnemius muscle of an 
ENU-mutant thy1.2-YFP16/WldS heterozygote, 3 days after section of the sciatic 
nerve. This mouse was designated CEMOP_S2 and showed strong deviation 
(synaptic protection) compared with the normal WldS/+ phenotype.  One of the 
frames from this movie is shown in Figure 3E. 
 
Supplementary Movie 4: Real-time images obtained by CME showing intact 
intramuscular axons and neuromuscular junctions in the gastrocnemius muscle of an 
ENU-mutant thy1.2-YFP16/WldS heterozygote, 3 days after section of the sciatic 
nerve. This mouse was designated CEMOP_S5 and showed strong deviation 
(synaptic protection) compared with the normal WldS/+ phenotype.  One of the 
frames from this movie is shown in Figure 3F. 
 
Supplementary Movie 5: Real-time images obtained by CME showing intact 
intramuscular axons and neuromuscular junctions in the axotomized muscle of the 
F1-offspring 1.1j from ENU-mutant CEMOP_S5 (See Figure 4). The gastrocnemius 
NMJ’s in this thy1.2-YFP16/WldS heterozygote were examined 3 days after section of 
the sciatic nerve. One of the frames from this movie is shown in Figure 4. 
 
Supplementary Movie 6: The 8-month old, liminally-symptomatic thy1.2-
YFP/SOD1G93A mouse from which images of NMJ’s shown in Figure 1 were 
subsequently obtained. The mouse only showed signs of abnormal gait, including 
splaying of the hind feet, before imaging with CME (Supplementary Movies 7,8). 
 
Supplementary Movie 7: Real-time images obtained by CME in the gastrocnemius 
muscle of the mouse shown in Supplementary Movie 6. One of the frames from this 
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movie is shown in Figure 6A. 
 
Supplementary Movie 8: Real-time images obtained by CME in the gastrocnemius 
muscle of the mouse shown in Supplementary Movie 6, four days after obtaining the 
movie shown in Supplementary Movie 7. One of the frames from this movie is shown 
in Figure 6B. 
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Name of 
Phenodeviant 
Modification of 
WldS/+ Phenotype 
Inheritance Test 
Results (+/+) 
Inheritance Test 
Results (WldS/+) 
CEMOP_A1 Axon degeneration N/A 0/21 (0%) 
CEMOP_S1 Synaptic protection 0/10 (0%) 0/15 (0%) 
CEMOP_S2 Synaptic protection 0/21 (0%) 2/16 (12.5%) 
CEMOP_S3 Synaptic protection 0/14 (0%) 5/16 (31.3%) 
CEMOP_S4 Synaptic protection 0/19 (0%) 0/17 (0%) 
CEMOP_S5 Synaptic protection 0/24 (0%) 17/25 (68%) 
CEMOP_S6 Synaptic protection 0/7 (0%) 0/14 (0%) 
  
Table 1 
Inheritance test results of phenodeviants identified in the ENU-mutagensis/ 
CME screen.   
One phenodeviant with enhanced axon degeneration and six phenodeviants with 
suppression of synaptic degeneration were identified in the screen. Inheritance test 
results from wild-type (+/+) mice were negative (0%) for all phenodeviants showing 
synaptic protection and WldS/+ inheritance test results of CEMOP_A1, CEMOP_S1, 
CEMOP_S4 and CEMOP_S6 were also negative (0%).  WldS/+ inheritance test 
results of CEMOP_S2 was 12.5% suggesting a low penetrance mutation. WldS/+ 
inheritance test results of CEMOP_S3 and CEMOP_S5 were approximately 31% and 
68% respectively suggesting Mendelian inheritance of a dominant mutation at least 
in the case of CEMOP_S5.   
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